This is the text extract for Widening of access to mycophenolate mofetil (CellCept), browse documents here.

18 May 2009

Widening of access to mycophenolate mofetil (CellCept)

PHARMAC is pleased to announce the approval of the proposal to widening of funded access to mycophenolate mofetil (CellCept) in the Pharmaceutical Schedule for use in liver transplant recipients from 1 July 2009. Details of the Decision From 1 July 2009 the Special Authority criteria for mycophenolate mofetil will be amended as follows to allow for its use following liver transplantation:

SAXXX Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following: 1 Renal transplant recipient; or 2 Heart transplant recipient; or 3 Liver transplant recipient; or 4 Patient has an organ transplant and has severe tophaceous gout making azathioprine unsuitable.

Feedback Received regarding the Proposal The widening of funded access to mycophenolate mofetil was the subject of a consultation letter dated 26 March 2009. We appreciate all the feedback we received and acknowledge the time people took to respond. All consultation responses received by 9 April 2009 were considered in their entirety in making a decision on the proposed change. All responses were supportive of the proposal. More information If you have any queries about these changes please contact the PHARMAC helpline on 0800 66 00 50 (9 am to 5 pm weekdays).